506943 Stock Overview
Manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
J. B. Chemicals & Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,885.70 |
| 52 Week High | ₹1,935.00 |
| 52 Week Low | ₹1,185.00 |
| Beta | -0.014 |
| 11 Month Change | 9.40% |
| 3 Month Change | 1.16% |
| 1 Year Change | 56.25% |
| 33 Year Change | 108.12% |
| 5 Year Change | 927.77% |
| Change since IPO | 73,994.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 506943 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 5.4% | 2.2% | -1.0% |
| 1Y | 56.2% | 46.7% | 43.6% |
Return vs Industry: 506943 exceeded the Indian Pharmaceuticals industry which returned 46.7% over the past year.
Return vs Market: 506943 exceeded the Indian Market which returned 43.6% over the past year.
Price Volatility
| 506943 volatility | |
|---|---|
| 506943 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.7% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 506943 has not had significant price volatility in the past 3 months.
Volatility Over Time: 506943's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 5,095 | Nikhil Chopra | www.jbpharma.com |
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company’s API product portfolio includes diclofenac sodium, dimethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides contract manufacturing services for tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms.
J. B. Chemicals & Pharmaceuticals Limited Fundamentals Summary
| 506943 fundamental statistics | |
|---|---|
| Market cap | ₹288.49b |
| Earnings (TTM) | ₹5.53b |
| Revenue (TTM) | ₹35.21b |
53.0x
P/E Ratio8.3x
P/S RatioIs 506943 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 506943 income statement (TTM) | |
|---|---|
| Revenue | ₹35.21b |
| Cost of Revenue | ₹11.82b |
| Gross Profit | ₹23.39b |
| Other Expenses | ₹17.87b |
| Earnings | ₹5.53b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 35.60 |
| Gross Margin | 66.43% |
| Net Profit Margin | 15.69% |
| Debt/Equity Ratio | 12.2% |
How did 506943 perform over the long term?
See historical performance and comparison